World Health Organisation (2014) Global status report on noncommunicable diseases. p xiv.http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf
Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94(3):311–321
Article
PubMed
Google Scholar
Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S14–S21
Article
PubMed
Google Scholar
National Institute for Cardiovascular Outcomes Research (NICOR) (2014) Myocardial Ischaemia National Audit Project Annual Public Report April 2013–March 2014. p 19. https://www.ucl.ac.uk/nicor/audits/minap/documents/annual_reports/minap-public-report-2014
Gibson CM (2004) NRMI and current treatment patterns for ST-elevation myocardial infarction. Am Heart J 148(5 Suppl):S29–S33
Article
PubMed
Google Scholar
Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351):13–20
Article
PubMed
Google Scholar
Pedersen F, Butrymovich V, Kelbaek H, Wachtell K, Helqvist S, Kastrup J et al (2014) Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 64(20):2101–2108
Article
PubMed
Google Scholar
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR et al (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316(7134):823–828
Article
PubMed Central
CAS
PubMed
Google Scholar
Singh M, Arora R, Kodumuri V, Khosla S, Jawad E (2011) Coronary revascularization in diabetic patients: current state of evidence. Exp Clin Cardiol 16(1):16–22
PubMed Central
PubMed
Google Scholar
Braunwald E, Kloner RA (1985) Myocardial reperfusion: a double-edged sword? J Clin Invest 76(5):1713–1719
Article
PubMed Central
CAS
PubMed
Google Scholar
Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357(11):1121–1135
Article
CAS
PubMed
Google Scholar
Piper HM, Garcia-Dorado D, Ovize M (1998) A fresh look at reperfusion injury. Cardiovasc Res 38(2):291–300
Article
CAS
PubMed
Google Scholar
Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I et al (2005) Postconditioning the human heart. Circulation 112(14):2143–2148
Article
PubMed
Google Scholar
Sivaraman V, Yellon DM (2014) Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. J Cardiovas Pharmacol Therap 19(1):83–96
Article
CAS
Google Scholar
Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM et al (2008) Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103(3):274–284
Article
CAS
PubMed
Google Scholar
Paiva M, Riksen NP, Davidson SM, Hausenloy DJ, Monteiro P, Goncalves L et al (2009) Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 53(5):373–378
Article
CAS
PubMed
Google Scholar
Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R et al (2008) Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 57(3):696–705
Article
CAS
PubMed
Google Scholar
Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM (2013) Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovas Drugs Therap Sponsored Int Soc Cardiovas Pharmacotherap 27(1):5–16
Article
CAS
Google Scholar
Paiva MA, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM (2010) Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovas Drugs Therap Sponsored Int Soc Cardiovas Pharmacotherap 24(1):25–32
Article
CAS
Google Scholar
Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E et al (2004) Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J 382(Pt 3):877–884
Article
PubMed Central
CAS
PubMed
Google Scholar
Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N et al (2005) Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54(7):2179–2187
Article
CAS
PubMed
Google Scholar
Solskov L, Lofgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT et al (2008) Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol 103(1):82–87
Article
CAS
PubMed
Google Scholar
Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25(12):2244–2248
Article
CAS
PubMed
Google Scholar
Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S et al (2010) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170(21):1892–1899
Article
CAS
PubMed
Google Scholar
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roqué i Figuls M, Moher D (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev (3):CD002966. doi:10.1002/14651858.CD002966.pub3
Lamanna C, Monami M, Marchionni N, Mannucci E (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13(3):221–228
Article
CAS
PubMed
Google Scholar
Zhao JL, Fan CM, Yang YJ, You SJ, Gao X, Zhou Q et al (2013) Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction. Cardiovasc Ther 31(1):60–64
Article
PubMed
Google Scholar
Lexis CP, Wieringa WG, Hiemstra B, van Deursen VM, Lipsic E, van der Harst P et al (2014) Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovas Drugs Therapy Sponsored Int Soc Cardiovasc Pharmacotherap 28(2):163–171
Article
CAS
Google Scholar
Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF et al (2014) Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 311(15):1526–1535
Article
PubMed
Google Scholar
Gore MO, McGuire DK, Lingvay I, Rosenstock J (2015) Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. Curr Cardiol Rep 17(7):607
Article
PubMed
Google Scholar